| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2006;47:640.)
© 2006 American Heart Association, Inc.
Editorial Commentaries |
From the Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
Correspondence to Michael Bader, Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Strasse 10, D-13125 Berlin, Germany. E-mail mbader@mdc-berlin.de
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
Chronic hypertension leads to adaptive processes in the heart, called remodeling, which are characterized by hypertrophic changes of cardiomyocytes and by structural alterations of the extracellular matrix. Although these processes are initially compensatory and preserve cardiac contractile performance, they finally lead to left ventricular (LV) dilatation and heart failure. Thus, factors playing a crucial role in remodeling are promising therapeutic targets.
Matrix metalloproteinases (MMPs) are proteolytic enzymes that are intimately involved in extracellular matrix remodeling. This family of >20 endopeptidases consists of collagenases (such as MMP-1 and MMP-13), stromelysins (MMP-3), and gelatinases (MMP-2 and MMP-9).1 The activity of MMPs is controlled by endogenous inhibitors called tissue inhibitors of metalloproteinases (TIMPs).
MMP-2 and MMP-9 are expressed by a multitude of cell types including cardiac myocytes and fibroblasts. It was reported that both enzymes are highly upregulated in hypertrophic and failing hearts, and they have been implicated in the progression of ventricular dilatation and the development of heart failure. However, MMP-2 and MMP-9 degrade type IV and V collagens, fibronectin, gelatins, laminin, and elastin, proteins that are accumulating in the damaged myocardium undergoing fibrosis. Thus, it is not clear whether MMPs are involved in the pathogenetic process of fibrosis or whether their upregulation represents a vain compensatory reaction.
In the current issue of Hypertension, Matsusaka et al2 evaluate effects of MMP-2 on structural and functional alterations of the left ventricle during cardiac hypertrophy because of pressure overload induced by transverse aortic constriction. They used an MMP-2 knockout (KO) mouse model, which
Related Article:
Hypertension 2006 47: 711-717.
This article has been cited by other articles:
![]() |
M. Nakagawa, G. Takemura, H. Kanamori, K. Goto, R. Maruyama, A. Tsujimoto, T. Ohno, H. Okada, A. Ogino, M. Esaki, et al. Mechanisms by Which Late Coronary Reperfusion Mitigates Postinfarction Cardiac Remodeling Circ. Res., July 3, 2008; 103(1): 98 - 106. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Doerries, K. Grote, D. Hilfiker-Kleiner, M. Luchtefeld, A. Schaefer, S. M. Holland, S. Sorrentino, C. Manes, B. Schieffer, H. Drexler, et al. Critical Role of the NAD(P)H Oxidase Subunit p47phox for Left Ventricular Remodeling/Dysfunction and Survival After Myocardial Infarction Circ. Res., March 30, 2007; 100(6): 894 - 903. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. M. Steinmetz, S. Sadaghiani, U. Panzer, C. Krebs, C. Meyer-Schwesinger, T. Streichert, S. Fehr, I. Hamming, H. van Goor, R. A. K. Stahl, et al. Antihypertensive therapy induces compartment-specific chemokine expression and a Th1 immune response in the clipped kidney of Goldblatt hypertensive rats Am J Physiol Renal Physiol, February 1, 2007; 292(2): F876 - F887. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-E Mo and L. F. Lau The Matricellular Protein CCN1 Is Essential for Cardiac Development Circ. Res., October 27, 2006; 99(9): 961 - 969. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |